Editas Medicine
Search results
Breaking new ground to advance science with the potential to change lives | Beam Therapeutics. Scroll down for more. Base Editing Applications. Base editing is an emerging class of investigational precision genetic medicines designed to overcome the limitations of existing approaches and expand the potential of genetic medicine.
Breaking new ground to advance science with the potential to change lives. Discover More. <p>Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.
Approach: Activation of fetal hemoglobin. BEAM-101 is an investigational therapy that produces base edits designed to potentially alleviate the effects of sickle cell disease by mimicking genetic variants seen in individuals who have hereditary persistence of fetal hemoglobin.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
May 30, 2024 · Beam Therapeutics is a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases.
Get the latest Beam Therapeutics Inc (BEAM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts.
Sep 5, 2023 · BEAM-201 is a quadruplex base-edited, anti-CD7 allogeneic chimeric antigen receptor T cell (CAR-T) under clinical investigation for the treatment of CD7+ relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma (T-ALL/T-LL).
Jan 8, 2024 · BEAM-302 is a potentially best-in-class liver-targeting LNP formulation of base editing reagents designed to correct the PiZ allele, the most common gene variant associated with severe AATD. Approximately 100,000 patients in the U.S. are estimated to carry the PiZZ genotype.
3 days ago · Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302,...
